RTI Biologics Reports $43.7M in Q1 Revenue, 8% Increase

RTI Biologics reported $43.7 million in first quarter revenues, an 8 percent increase over the same period in 2011.

Advertisement

Reported net income was $2 million for the first quarter, up from $1.2 million last year. The company attributes its success to its direct sports medicine and BGS/GO implants. The company is investing in new product development initiatives and direct distribution this year, which could positively impact future revenue growth.

More Articles on Orthopedic Device Companies:

AlloSource Hires Dale Binke as Vice President of Marketing & Sales

Orthofix Sells Sports Medicine Business for $157.5M

Johnson & Johnson Q1 Orthopedic Sales Flat

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.